F. Rolland
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies 8
-
- Cancer Treatment and Pharmacology 8
- Lung Cancer Research Studies 4
-
- Lung Cancer Treatments and Mutations 6
- Prostate Cancer Treatment and Research 5
- Prostate Cancer Diagnosis and Treatment 3
- Renal cell carcinoma treatment 2
- Ophthalmology top 10%
-
- Chemotherapy-induced organ toxicity mitigation 2
F. Rolland
28 papers receiving 446 citations
Peers
Comparison fields: 5 of 67
- Otorhinolaryngology 135
- Oncology 230
- Pulmonary and Respiratory Medicine 164
- Ophthalmology 28
- Cancer Research 41
Countries citing papers authored by F. Rolland
This map shows the geographic impact of F. Rolland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Rolland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Rolland more than expected).
Fields of papers citing papers by F. Rolland
This network shows the impact of papers produced by F. Rolland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Rolland. The network helps show where F. Rolland may publish in the future.
Co-authorship network
The 25 scholars most cited alongside F. Rolland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 49 | |
| 2 | 2020 | 5 | |
| 3 | 2015 | 4 | |
| 4 | 2013 | 15 | |
| 5 | 2011 | 3 | |
| 6 | 2011 | 4 | |
| 7 | 2011 | 2 | |
| 8 | 2011 | 6 | |
| 9 | 2010 | 0 | |
| 10 | 2009 | 2 | |
| 11 | 2005 | 23 | |
| 12 | 2004 | 30 | |
| 13 | 2001 | 10 | |
| 14 | 1998 | 21 | |
| 15 | Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. | 1998 | 96 |
| 16 | 1997 | 9 | |
| 17 | 1997 | 5 | |
| 18 | 1997 | 6 | |
| 19 | [Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination]. | 1995 | 3 |
| 20 | Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. | 1995 | 15 |
About F. Rolland
F. Rolland is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Dermatology, having authored 29 papers that have together received 457 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Head and Neck Cancer Studies (8 papers), Lung Cancer Treatments and Mutations (6 papers), Prostate Cancer Treatment and Research (5 papers), Lung Cancer Research Studies (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers), Chemotherapy-induced organ toxicity mitigation (2 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Otorhinolaryngology (135 citations), Oncology (230 citations), Pulmonary and Respiratory Medicine (164 citations), Ophthalmology (28 citations) and Cancer Research (41 citations). F. Rolland has collaborated with scholars based in France, Belgium and Switzerland. Frequent co-authors include Thierry Conroy, G. Milano, Muriel Barberi‐Heyob, Jean‐Louis Merlin, A. Riviére, R. Féty, Agnès Hardouin, L. Campion, M C Etienne and G. Perrocheau. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Oral Oncology and Ocular Immunology and Inflammation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.